Sernova Biotherapeutics reports developments tied to its clinical-stage regenerative medicine programs, including the Cell Pouch Bio-hybrid Organ being developed for type 1 diabetes. Company news centers on clinical and regulatory updates, research collaborations involving donor cells, stem-cell derived islet-like clusters and immunosuppression approaches, and the advancement of its bio-hybrid organ platform.
Recurring updates also cover Sernova's capital structure, including private placements, debt settlements, convertible debentures, warrant issuances and debt-to-equity conversions. Governance items include annual meeting results, board composition and shareholder voting matters.
Sernova Biotherapeutics (SEOVF) has secured a CAD$1 million unsecured convertible debenture financing from board member Dr. Steven Sangha. The debenture, maturing on March 4, 2027, carries a 15% interest rate and is convertible into common shares at CAD$0.20 per share.
The company also issued 5 million non-transferable share purchase warrants, exercisable at CAD$0.20 per share until March 4, 2028. The financing proceeds will be used for working capital. The transaction, classified as a 'related party transaction,' is exempt from formal valuation and minority shareholder approval requirements as it represents less than 25% of the company's market capitalization.
Sernova Biotherapeutics (SEOVF) has received FDA clearance for its Investigational New Drug (IND) application to evaluate the Cell Pouch bio-hybrid organ with auto-transplanted thyroid cells in patients undergoing thyroid surgery. The therapy aims to treat hypothyroidism in patients post-thyroid surgery.
The Cell Pouch system, combined with autologous thyroid cell therapy, is designed to restore natural thyroid function without requiring thyroid hormone replacement medications or immune suppression therapy. Preclinical studies have shown successful restoration of primary thyroid hormones (T4 and T3) to pre-thyroidectomy levels when thyroid tissue was re-implanted into the pre-vascularized Cell Pouch. Healthy, functional thyroid tissue was confirmed through radio-isotope imaging and histological analysis up to five months post-implantation.
Sernova Biotherapeutics (SEOVF) has submitted an Investigational New Drug (IND) application to the FDA for its Cell Pouch bio-hybrid organ with autologous thyroid cells to treat hypothyroidism in patients undergoing total thyroidectomy. The technology aims to restore natural thyroid function without requiring immune suppression therapy.
Preclinical trials have shown promising results, demonstrating that reimplanting thyroid tissue into the pre-vascularized Cell Pouch restored thyroxine (T4) and triiodothyronine (T3) hormones to pre-thyroidectomy levels without hormone supplementation. Imaging and histology confirmed functional thyroid tissues within the Cell Pouch five months post-reimplantation.
Upon FDA clearance, Sernova plans to initiate a first-in-human clinical trial to evaluate safety, tolerability, and efficacy in patients undergoing thyroidectomy for benign nodular disease.
Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) has appointed Ross Haghighat as Chair of the Board. Haghighat brings over three decades of experience in founding, funding, and scaling technology ventures in healthcare, with expertise in driving successful innovations, strategic growth, and mergers and acquisitions in the biotechnology sector.
The company, which focuses on developing Cell Pouch bio-hybrid organ as a functional cure for Type 1 diabetes (T1D), also announced its corporate continuance from the Canada Business Corporations Act to the Business Corporations Act (British Columbia). Additionally, the company has changed its name from Sernova Corp. to Sernova Biotherapeutics Inc., while maintaining its existing ticker symbols.
Sernova Corp. (TSX: SVA, OTCQB: SEOVF, FSE/XETRA: PSH) announced the results of its annual and special general meeting held virtually on January 10, 2025. A total of 74,190,067 common shares were voted, representing 22.8% of all outstanding shares as of November 12, 2024.
Key resolutions approved include the election of six directors: Tanya Lewis (99.6% for), Bernd Muehlenweg (99.7% for), David Paterson (99.4% for), Jonathan Rigby (99.4% for), Steven Sangha (99.4% for), and Ross Haghighat (99.5% for). KPMG LLP was appointed as auditors until the next annual meeting. Other approved resolutions include the continuance as a British Columbia , adoption of new articles, alteration of the share structure to add unlimited Preferred Shares, and an increase in the maximum number of common shares reserved for stock option grants to 50,000,000.
A conditional grant of 5,500,000 options was also approved for officers under the Option Plan. Jonathan Rigby, Sernova’s President and CEO, expressed gratitude for the shareholders' support, emphasizing the company's strengthened management team, new corporate branding, and reinvigorated corporate culture.
Sernova Corp (TSX: SVA) (OTCQB: SEOVF) has rescheduled its annual general and special meeting of shareholders from January 7, 2025, to January 10, 2025, at 1:00pm ET. The postponement is due to a recent postal strike in Canada, which affected the company's ability to mail meeting materials through Canada Post to meet regulatory requirements. The record date remains November 12, 2024.
Shareholders must submit their proxies by 1:00 p.m. ET on January 8, 2025, either through TMX Trust Company, by telephone, or online. The Management Information Circular is available on Sernova's website and SEDAR+ profile.
Sernova Corp (TSX: SVA, OTCQB: SEOVF) announced key strategic initiatives, including a non-binding letter of intent with HealthGena and GOLDTRACK Ventures for 'Project REEM Ventures' to explore product development and commercialization opportunities in Saudi Arabia for type 1 diabetes treatment. The company also welcomed Dr. Robert Gabbay, former Chief Scientific and Medical Officer at the American Diabetes Association, as a clinical advisor. Sernova will host a virtual Town Hall on December 13 and hold its Annual General Meeting on January 7, 2025. The company is developing a Cell Pouch bio-hybrid organ as a potential functional cure for type 1 diabetes and thyroid disorders.
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) has announced positive interim data from its ongoing Phase I/II clinical trial of the Cell Pouch Transplant System for type 1 diabetes (T1D). The trial shows sustained insulin independence in all 6 patients of Cohort A after islet transplantation. Notably, histological data from a patient's explanted Cell Pouch after 5+ years revealed abundant, well-vascularized, functioning islets producing insulin, glucagon, and somatostatin. The Cell Pouch demonstrated no evidence of fibrosis or degradation after long-term implantation. Sernova plans to complete Cohort B soon and initiate Cohort C with an optimized immune suppression regimen. The company is also developing iPSC-derived islet-like clusters with partner Evotec for a scalable cell source.
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF), a clinical-stage biotech company focusing on regenerative medicine cell therapies, has appointed Jonathan Rigby as its new CEO. Rigby, a type 1 diabetic himself, brings extensive experience in raising capital, leading biotech companies to Nasdaq listings, and achieving strategic acquisitions. The Board believes Rigby's leadership will position Sernova to achieve its strategic milestones.
Rigby's background includes several CEO roles and board positions in biotech companies, particularly in the diabetes field. He holds a degree in biological sciences and an MBA. The appointment aims to drive Sernova's growth and realize its full potential in developing treatments for chronic diseases, including its ongoing phase 1/2a clinical trial in type 1 diabetes.
Summary not available.